What do systematic reviews say?

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (vomiting) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.76 [0.35, 1.63]
  1 study · 107 participants
  Low

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (diarrhoea) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.82 [0.38, 1.76]
  1 study · 107 participants
  Low

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in patient satisfaction with analgesia compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.97 [0.42, 2.21]
  1 study · 104 participants
  Low

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in patient satisfaction with abortion care overall compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 1.84 [0.8, 4.22]
  1 study · 105 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 1.52 [0.53, 4.37]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg may leads to lower gastrointestinal side effects (vomiting) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.19 [0.04, 0.97]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg showed no clear difference in complete abortion rate compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.69 [0.17, 2.85]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 67 participants
  Very low

Short‐acting inhaled muscarinic antagonists vs placebo

The review found no eligible studies for this question.

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

The review found no eligible studies for this question.

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

• Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 27 participants
  Very low